| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.DET.2010.09.006 |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:S0733863510001786?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:S0733863510001786?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 21095521 |
| P50 | author | Françoise Portaels | Q30112618 |
| P2093 | author name string | Wayne M. Meyers | |
| Douglas S. Walsh | |||
| P2860 | cites work | Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs | Q21090122 |
| Application of real-time PCR in Ghana, a Buruli ulcer-endemic country, confirms the presence of Mycobacterium ulcerans in the environment | Q39552857 | ||
| Single nucleotide polymorphisms on the road to strain differentiation in Mycobacterium ulcerans | Q41838628 | ||
| Correlation between Buruli ulcer and vector-borne notifiable diseases, Victoria, Australia | Q43143284 | ||
| Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. | Q43170874 | ||
| Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events | Q43204610 | ||
| IFN-gamma-dependent activation of macrophages during experimental infections by Mycobacterium ulcerans is impaired by the toxin mycolactone | Q43222932 | ||
| Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease | Q43253448 | ||
| The local immune response in ulcerative lesions of Buruli disease. | Q44814557 | ||
| Differences in virulence and immune response induced in a murine model by isolates of Mycobacterium ulcerans from different geographic areas. | Q45928623 | ||
| A comparison of DNA extraction procedures for the detection of Mycobacterium ulcerans, the causative agent of Buruli ulcer, in clinical and environmental specimens | Q47262740 | ||
| Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans | Q57203196 | ||
| Association of HIV infection and Mycobacterium ulcerans disease in Benin | Q81126307 | ||
| Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer) | Q83390284 | ||
| Buruli ulcer | Q83638686 | ||
| First cultivation and characterization of mycobacterium ulcerans from the environment | Q21092307 | ||
| Seasonal and regional dynamics of M. ulcerans transmission in environmental context: deciphering the role of water bugs as hosts and vectors | Q21562264 | ||
| Detection of Mycolactone A/B in Mycobacterium ulcerans-Infected Human Tissue | Q28472261 | ||
| Genomic diversity and evolution of mycobacterium ulcerans revealed by next-generation sequencing | Q28751756 | ||
| Mycolactone gene expression is controlled by strong SigA-like promoters with utility in studies of Mycobacterium ulcerans and buruli ulcer | Q30914398 | ||
| Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial | Q33409842 | ||
| Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer | Q33511900 | ||
| "Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. | Q33515905 | ||
| Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease). | Q33631299 | ||
| Single nucleotide polymorphism typing of mycobacterium ulcerans reveals focal transmission of buruli ulcer in a highly endemic region of Ghana | Q33638463 | ||
| Under treated necrotizing fasciitis masquerading as ulcerated edematous Mycobacterium ulcerans infection (Buruli ulcer). | Q33693677 | ||
| Buruli ulcer in United Kingdom tourist returning from Latin America | Q33800627 | ||
| Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans | Q33938119 | ||
| Terrestrial small mammals as reservoirs of Mycobacterium ulcerans in benin | Q33963439 | ||
| Family relationship, water contact and occurrence of Buruli ulcer in Benin | Q33991576 | ||
| Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. | Q34108789 | ||
| BCG vaccine effectiveness against Buruli ulcer: a case-control study in Benin. | Q34571722 | ||
| Comparative study of the sensitivity of different diagnostic methods for the laboratory diagnosis of Buruli ulcer disease | Q34960357 | ||
| Heterogeneity among Mycobacterium ulcerans isolates from Africa. | Q36029417 | ||
| Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease | Q36227714 | ||
| The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection | Q36253353 | ||
| Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease) | Q36295353 | ||
| Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice | Q36703065 | ||
| Buruli ulcer disease: prospects for a vaccine | Q37387041 | ||
| Lack of insertional-deletional polymorphism in a collection of mycobacterium ulcerans isolates from Ghanaian buruli ulcer patients | Q37410568 | ||
| Risk factors for Mycobacterium ulcerans infection | Q37698814 | ||
| Laboratory diagnosis of Buruli ulcer disease | Q37704358 | ||
| Short report: Clinical and molecular evidence for a case of Buruli ulcer (Mycobacterium ulcerans infection) in Kenya | Q38873337 | ||
| The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda | Q38893413 | ||
| Outcome of patients with buruli ulcer after surgical treatment with or without antimycobacterial treatment in Ghana. | Q39440301 | ||
| VNTR analysis differentiates Mycobacterium ulcerans and IS2404 positive mycobacteria | Q39493103 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Mycobacterium ulcerans | Q141154 |
| P304 | page(s) | 1-8 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Dermatologic Clinics | Q15758379 |
| P1476 | title | Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection | |
| Buruli Ulcer: Advances in Understanding Mycobacterium ulcerans Infection | |||
| P478 | volume | 29 |
| Q54224351 | A protocol for culturing environmental strains of the Buruli ulcer agent, Mycobacterium ulcerans. |
| Q39551255 | Bacterial diversity in Buruli ulcer skin lesions: Challenges in the clinical microbiome analysis of a skin disease |
| Q28487137 | Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease |
| Q39615760 | Beninese Medicinal Plants as a Source of Antimycobacterial Agents: Bioguided Fractionation and In Vitro Activity of Alkaloids Isolated from Holarrhena floribunda Used in Traditional Treatment of Buruli Ulcer |
| Q35989764 | Burden and Historical Trend of Buruli Ulcer Prevalence in Selected Communities along the Offin River of Ghana |
| Q59356163 | Buruli Ulcer in Sub-Saharan Africa |
| Q46241939 | Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans |
| Q34229628 | Buruli ulcer |
| Q42593134 | Buruli ulcer disease in Republic of the Congo |
| Q36363023 | Buruli ulcer disease in travelers and differentiation of Mycobacterium ulcerans strains from northern Australia |
| Q34500901 | Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection |
| Q34235687 | Detection of Mycobacterium ulcerans by the Loop-mediated Isothermal Amplification Method |
| Q88053869 | Diagnostic Accuracy of Clinical and Microbiological Signs in Patients With Skin Lesions Resembling Buruli Ulcer in an Endemic Region |
| Q34779036 | Geographic distribution, age pattern and sites of lesions in a cohort of Buruli ulcer patients from the Mapé Basin of Cameroon |
| Q53702000 | Inhibition of Sec61-dependent translocation by mycolactone uncouples the integrated stress response from ER stress, driving cytotoxicity via translational activation of ATF4. |
| Q37545814 | Insertion sequence element single nucleotide polymorphism typing provides insights into the population structure and evolution of Mycobacterium ulcerans across Africa |
| Q55365530 | Laboratory confirmation of Buruli ulcer cases in Ghana, 2008-2016 |
| Q38068498 | Laboratory procedures for the detection and identification of cutaneous non-tuberculous mycobacterial infections. |
| Q34299710 | Macrophage cytokines: involvement in immunity and infectious diseases |
| Q40054248 | Mapping biopsy for Buruli ulcer self-medicated with occlusive dressing |
| Q40794641 | Mechanistic insights into the inhibition of Sec61-dependent co- and post-translational translocation by mycolactone. |
| Q48105775 | Membrane perturbing properties of toxin mycolactone from Mycobacterium ulcerans |
| Q34630531 | Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease |
| Q57776721 | Modular total syntheses of mycolactone A/B and its [2H]-isotopologue |
| Q35107244 | Multicenter external quality assessment program for PCR detection of Mycobacterium ulcerans in clinical and environmental specimens |
| Q36264288 | Multiple Introductions and Recent Spread of the Emerging Human Pathogen Mycobacterium ulcerans across Africa |
| Q35145362 | Mycobacterium ulcerans Fails to Infect through Skin Abrasions in a Guinea Pig Infection Model: Implications for Transmission |
| Q61798918 | Mycobacterium ulcerans Population Genomics To Inform on the Spread of Buruli Ulcer across Central Africa |
| Q38044475 | Mycobacterium ulcerans infection: evolution in clinical management |
| Q35133550 | Mycobacterium ulcerans persistence at a village water source of Buruli ulcer patients |
| Q38951193 | Mycolactone reveals the substrate-driven complexity of Sec61-dependent transmembrane protein biogenesis. |
| Q27318699 | Mycolactone-Dependent Depletion of Endothelial Cell Thrombomodulin Is Strongly Associated with Fibrin Deposition in Buruli Ulcer Lesions |
| Q37115277 | Mycolactone-mediated neurite degeneration and functional effects in cultured human and rat DRG neurons: Mechanisms underlying hypoalgesia in Buruli ulcer |
| Q35530457 | Nineteen cases of Buruli ulcer diagnosed in Japan from 1980 to 2010. |
| Q34702499 | Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model |
| Q38180777 | Pleiotropic molecular effects of the Mycobacterium ulcerans virulence factor mycolactone underlying the cell death and immunosuppression seen in Buruli ulcer |
| Q34687435 | Primary cultivation: Factors affecting contamination and Mycobacterium ulcerans growth after long turnover time of clinical specimens |
| Q47709186 | Risk factors for Mycobacterium ulcerans infection (Buruli Ulcer) in Togo ─ a case-control study in Zio and Yoto districts of the maritime region |
| Q47151971 | Successful treatment of erythema induratum with topical application of antituberculous drugs: A case report |
| Q48269589 | The potent effect of mycolactone on lipid membranes. |
| Q35625819 | Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? |
Search more.